INTERPACE BIOSCIENCES, INC. (IDXG)
2025-06-30 | 2025-03-31 | 2024-09-30 | 2024-06-30 | |
|---|---|---|---|---|
| Revenue, net | 9,232 | 11,515 | 12,295 | 12,042 |
| Cost of revenue | 3,956 | 4,145 | 4,789 | 4,611 |
| Gross profit | 5,276 | 7,370 | 7,506 | 7,431 |
| Sales and marketing | 2,910 | 2,814 | 2,864 | 2,887 |
| Research and development | 173 | 177 | 199 | 146 |
| General and administrative | 2,661 | 2,550 | 2,538 | 2,141 |
| Total operating expenses | 5,744 | 5,541 | 5,601 | 5,174 |
| Operating (loss) income from continuing operations | -468 | 1,829 | 1,905 | 2,257 |
| Note payable interest | 49 | 78 | 141 | 176 |
| Interest accretion expense | - | - | 4 | 12 |
| Other (expense) income, net | -16 | 21 | - | - |
| Other nonoperating expense | - | - | 394 | - |
| Other income (expense), net | - | - | - | 71 |
| (loss) income from continuing operations before tax | -533 | 1,772 | 1,366 | 2,140 |
| Provision for income taxes | - | 18 | 4 | 4 |
| (loss) income from continuing operations | -533 | 1,754 | 1,362 | 2,136 |
| Loss from discontinued operations, net of tax | -107 | -107 | -82 | -74 |
| Net (loss) income | -640 | 1,647 | 1,280 | 2,062 |
| Basic | 4,423,000 | 4,420,000 | 4,393,000 | 4,376,000 |
| Diluted | 4,423,000 | 27,704,000 | 4,423,000 | 4,401,000 |
| Net income (loss) per basic share of common stock | -0.14 | 0.37 | 0.29 | 0.47 |
| Net income (loss) per diluted share of common stock | -0.14 | 0.06 | 0.29 | 0.47 |